ContraFect to Present at Cantor Antibiotics Summit
January 11, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at 10th Annual Biotech Showcase
January 03, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 15, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
November 10, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Third Quarter 2017 Financial Results
November 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Melinta Therapeutics Announces Successful Completion of Merger
November 06, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
October 30, 2017 08:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
ContraFect to Present New Data on CF-301 at ID Week 2017
September 29, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at The MicroCap Conference
September 28, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens
September 18, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...